Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use

Papp, Zoltán and Agostoni, Piergiuseppe and Alvarez, Julian and Bettex, Dominique and Bouchez, Stefan and Édes, István and Papp, Julius G. (2020) Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 76 (1). pp. 4-22. ISSN 0160-2446 (print); 1533-4023 (online)

Preview

Text PappZJCardiovascPharmacol2020.pdf Download (819kB) | Preview

Abstract

Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart failure (HF). In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitization and promotes vasodilatation through the opening of adenosine triphosphate-dependent potassium channels on vascular smooth muscle cells, has been approved in more than 60 jurisdictions, including most of the countries of the European Union and Latin America. Areas of clinical application have expanded considerably and now include cardiogenic shock, takotsubo cardiomyopathy, advanced HF, right ventricular failure, pulmonary hypertension, cardiac surgery, critical care, and emergency medicine. Levosimendan is currently in active clinical evaluation in the United States. Levosimendan in IV formulation is being used as a research tool in the exploration of a wide range of cardiac and noncardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral sclerosis. To mark the 20 years since the advent of levosimendan in clinical use, 51 experts from 23 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, the United Kingdom, and Ukraine) contributed to this essay, which evaluates one of the relatively few drugs to have been successfully introduced into the acute HF arena in recent times and charts a possible development trajectory for the next 20 years.

Actions (login required)

Edit Item